evidence:  and a 39% improvement in fatigue-disrupted quality of life (MD = 11.76, 95% CI 4.65, 18.86; P = 0.002), a large effect (d = 0.76)
intervention: open-label placebo (OLP)
comparator: treatment as usual (TAU)
outcome: fatigue-disrupted quality of life